KURA - NASDAQ

Good day everyone and welcome to today’s First Quarter 2025 Kura Oncology Financial Results Conference Call. At this time, all participants are in a listen-only mode. Later you will have the opportunity to ask questions during the question-and-answer session. [Operator Instructions] Please note this call may be recorded and I will be standing by if you should need any assistance. It is now my pleasure to turn the conference over to Apoorva Shilori [ph]. Please go ahead.

Thank you, operator. Good afternoon, and welcome to Kura Oncology’s first quarter 2025 conference call. Joining me on the call are Dr. Troy Wilson, President and Chief Executive Officer; Dr. Mollie Leoni, Chief Medical Officer; Brian Powl, Chief Commercial Officer; and Tom Doyle, Senior Vice President of Finance and Accounting. Before I turn the call over to Dr. Wilson, I’d like to remind you that today’s call will include forward-looking statements based on current expectations. Such statements represent management’s judgment as of today and may involve risks and uncertainties that could cause actual results to differ materially from expected results. Please refer to Kura’s filings with the SEC, which are available from the SEC or on the Kura Oncology website for information concerning risk factors that could affect the company. With that, I’ll turn the call over to Troy.

Thank you, Apoorva. Good afternoon and thank you all for joining us. Over the past quarter we’ve made substantial progress executing against our pipeline. We’ve achieved important clinical and regulatory milestones, which have clinically and financially de-risked our preparations to commercialize ziftomenib in acute myeloid leukemia, or AML, including the recent NDA submission for ziftomenib as a monotherapy, including in relapsed or refractory NPM1-mutant AML. The ziftomenib monotherapy Phase 2 registrational data were accepted for oral presentation at the 2025 ASCO Annual Meeting, which will be the first of multiple clinical data updates we anticipate presenting at major oncology medical meetings throughout this year. Earlier this week, we announced the first patients with advanced gastrointestinal stromal tumors, or GIST, after imatinib failure were dosed with the combination of ziftomenib and imatinib. Our FTI program continues to advance and we expect to share preliminary clinical data from multiple Phase 1 cohorts later this year, evidencing the potential of FTIs as combination therapies. As we continue to build Kura into a fully integrated organization, we’re pleased to announce the appointment of Samir Vattompadam to our leadership team as Senior Vice President, Global Program Leadership. Samir joins Kura with more than 20 years of experience in the biotech and pharmaceutical industry, including extensive leadership of Global Program teams, which have driven the development and commercialization of 16 novel medicines and indications across 13 diseases, primarily in oncology and hematology. As adjusted for the $45 million milestone payment under our collaboration agreement with Kyowa Kirin, upon receipt by FDA of the NDA submission for ziftomenib, Kura had on a pro forma basis $703.2 million in cash, cash equivalents and short-term investments as of March 31st, 2025. Accounting for the $45 million milestone payment, we stand to receive an additional $375 million in near-term anticipated milestones. This strong cash position provides sufficient capital to fund our ziftomenib AML program to commercialization in the frontline setting as well as advance our pipeline to multiple value inflection points. With that overview, let’s now dive in starting with ziftomenib. On March 31st, we submitted our New Drug Application, or NDA, for ziftomenib, our once daily oral investigational menin inhibitor. As a reminder, ziftomenib is the first and only investigational therapy to be granted Breakthrough Therapy Designation for treatment of relapsed or refractory NPM1-mutant AML. There are no FDA approved therapies targeting NPM1-mutant AML, which represents approximately 30% of new AML cases annually and is a disease of significant unmet need. Priority review was requested, which if granted would provide a target FDA review period of six months from NDA acceptance. FDA has been a collaborative and supportive partner. And although it’s early days in our review cycle, we’ve not experienced any disruptions or delays due to the changes underway at Health and Human Services, or FDA. We look forward to continuing to work closely with the agency throughout the review process and are optimistic about the potential for ziftomenib to impact patients with relapsed/refractory NPM1-mutant AML. With that introduction, I’d like to turn it over to Mollie to walk through updates to our development pipeline and programs. Mollie?

Thank you, Troy. First, let’s start with our ziftomenib development program. Earlier this year, we announced KOMET-001, our Phase 2 registration-directed trial of ziftomenib in patients with relapsed/refractory NPM1-mutant AML had achieved its primary CR/CRh endpoint and we are pleased the data will be shared in an oral presentation at the upcoming 2025 ASCO Annual Meeting in Chicago. The benefit risk profile for ziftomenib in this patient population is highly encouraging and the safety profile remains consistent with data shared previously. We believe the combination of favorable safety and tolerability profile and clinical activity in this once daily oral medication support a competitive profile in the relapsed/refractory setting as well as clinical development in the critical frontline indications. Our plan is to socialize the data among the scientific and medical communities in the U.S. and Europe between the oral presentation at ASCO as well as an encore presentation of the data at the 2025 EHA Congress ahead of potential marketing approval. Moving to the combinations, we continue to see robust enrollment in both the KOMET-007 and 008 studies, which are evaluating ziftomenib in combination with various standards of care. We are pleased to announce the preliminary clinical data from the Phase 1b expansion cohort evaluating the combination of ziftomenib with intensive chemotherapy in the frontline setting has been accepted for an oral presentation at EHA and we anticipate presenting preliminary clinical data from the 007 Phase 1b expansion cohort evaluating ziftomenib in combination with venetoclax and azacitidine in the frontline setting in the second half of the year. These will be important updates as they will help inform the safety, tolerability and potential clinical activity of the triplet combinations and directly inform the design and conduct of the Phase 3 frontline trials under the KOMET-017 protocol. In addition, we announced last quarter we had reached alignment with FDA and EMA for the design and conduct of this trial. Notably, we also announced we had broken new ground to use MRD-negative CR and CR respectively as primary endpoints for accelerated approval in the United States in the intensive and non-intensive chemotherapy frontline trials, respectively. As a reminder, the global protocol comprises of two independent randomized, double-blind, placebo-controlled Phase 3 trials to evaluate ziftomenib in combination with both intensive and non-intensive combination regimens in patients with newly diagnosed NPM1-mutant or KMT2A-rearranged AML. We have received feedback from institutions, investigators and their study teams that the design of KOMET-017 with two independent Phase 3 trials under a single protocol is very attractive to clinical sites because it simplifies trial startup and conduct and provides a single option to nearly all of their eligible frontline patients. KOMET-017 is now in study startup and we remain on track to initiate the studies in the second half of this year. Turning our attention to solid tumors. Earlier this week, we announced the first patients dosed in our Phase 1 KOMET-015 trial to evaluate the safety, tolerability and preliminary antitumor activity and ziftomenib in combination with imatinib in adults with GIST, who are currently on or have previously been treated with imatinib therapy. Approximately 4,000 to 6,000 new cases of GIST are diagnosed each year in the U.S. and advanced GIST patients have limited treatment options. The current frontline standard of care regimen in these advanced patients is imatinib, which targets KIT inhibition. The challenge is most patients eventually develop resistance to imatinib due to the development of secondary KIT mutations. TKIs such as sunitinib target imatinib-resistant genotypes and are approved in later lines, but response rates and long-term outcomes are modest, so new therapeutic options are needed.

Thank you, Mollie. Regarding the dynamic macro landscape in which we’re now operating, we continue to monitor developments and remain vigilant to the rapidly evolving situation and we’re prepared to adapt as needed. At this time, we believe the impact from tariffs would be negligible. And additionally, all of our intellectual property is domiciled in The United States. Importantly, in this challenging market, our strategic partnership with Kyowa Kirin provides us with greater development, commercial and operational resources, as well as increased financial stability. Our partnership and cash resources enable our team to stay focused and execute on our pre commercial and launch preparation efforts, as well as our efforts to create a clinically meaningful impact in other areas such as GIST, renal cell carcinoma and other solid tumors. I’ll now turn it over to Tom to provide the first quarter financial highlights. Tom?

Thank you, Troy. And good afternoon, everyone. Collaboration revenue from our Kyowa Kirin partnership for the first quarter of 2025 was $14.1 million compared to no revenue in the first quarter of 2024. Research and development expenses for the first quarter of 2025 were $56 million compared to $36.3 million for the first quarter of 2024. General and administrative expenses for the first quarter of 2025 were $22.8 million compared to $18.2 million for the same period in 2024. Net loss for the first quarter of 2025 was $57.4 million compared to a net loss of $49.5 million for the first quarter of 2024. This included non-cash, share-based compensation expense of $7.8 million compared to $8.5 million for the same period in 2024. As of March 31, 2025, Kura had cash, cash equivalents, and short term investments of $658.2 million compared to $727.4 million as of December 31, 2024. As adjusted for the $45 million NDA submission milestone payment under our collaboration agreement with Kyowa Kirin, Kura had on a pro form a basis $703.2 million in cash, cash equivalents and short term investments as of March 31, 2025. Based on our current operating plans, we believe that our cash, cash equivalents and short term investments as of the end of the first quarter will be sufficient to fund our current operating expenses into 2027. If we include anticipated collaboration funding and milestones under the Kyowa agreement, Kura’s financial resources should support advancement of our ziftomenib AML program through commercialization in the frontline combination setting. With that I will turn the call back over to Troy.

Thank you, Tom. Before we jump into the question-and-answer session, let me lay out our anticipated upcoming milestones. For ziftomenib and our menin inhibitor programs, we look forward to presenting full data for KOMET-001 in Q2 2025 in an oral presentation at ASCO and an encore presentation at EHA, present preliminary clinical data from the KOMET-007 Phase 1b expansion cohort evaluating ziftomenib with intensive chemotherapy or seven plus three in the frontline setting at EHA, presenting preliminary clinical data from the KOMET-007 Phase 1b expansion cohort evaluating ziftomenib with venetoclax and azacitidine in the frontline setting at a medical meeting in the second half of 2025, initiating KOMET-007 two independent Phase 3 registration enabling trials in frontline intensive and non-intensive AML in the second half of 2025 and nominating a development candidate for a next generation menin inhibitor program in diabetes in mid-2025. For our farnesyl transferase inhibitor programs, we expect the following milestones: initiate one or more expansion cohorts of KO-2806 and cabozantinib in patients with advanced renal cell carcinoma in second half 2025; present data from the FIT-001 Phase 1 trial evaluating KO-2806 and cabozantinib in patients with renal cell carcinoma in the second half of 2025; present data from the FIT-001 Phase 1 monotherapy dose escalation of KO-2806 in patients with RAS mutations in second half 2025; and finally, to present data from the current HN trial evaluating tipifarnib and alpelisib in PIK3CA-mutant head and neck squamous cell carcinoma in the second half of 2025. With that, Jess, we’re now ready for questions.

Thank you, sir. [Operator Instructions] We will move first to Li Watsek with Cantor Fitzgerald.

Hi, team. This is Dan [ph] on for Li. Congrats on the progress and the milestone payment. Can you maybe set the expectations for the combo data coming later this year, especially the aza/ven cohort? What do you need to show us to be competitive? It looks like some of your competitors have kicked off a Phase 3 trial here. Just update us a little bit as well what you’re thinking about in terms of initiating the frontline trial. Thanks.

Yes, thanks, Dan [ph], for the questions. So just to recap, so what are we looking for from the aza/ven cohort and then really timing of initiation of that trial relative to the competition. Mollie, would you like to take Dan’s [ph] questions?

Sure. As I’ll remind you, we’re always looking for, especially in these preliminary data presentations, safety as our first, second and third priorities. So, the ability to safely combine our ziftomenib with the ven in the frontline is what we really want to establish. And obviously now being able to finally see the data in these frontline patients, we’ll be able to see some additional characteristics about time on treatment and overall patients’ responses to therapy. So, we look forward to being able to show you the combinability of ziftomenib with these agents that can be difficult to combine with if there was to be any added toxicity or any adverse events on combination.

And Dan [ph], with respect to your question around timing, we remain on track to start the study in the second half of 2025.

Okay, thank you.

Sure.

We’ll go to Jonathan Chang with Leerink Partners.

Hi, guys. Thanks for taking my questions. First question, can you discuss how the changes at the regulatory agency have impacted or not the potential approval process and timelines for ziftomenib? The second question… Troy go ahead.

Yes, go ahead, Jonathan. Go ahead. No, no, go ahead.

The second question, can you help set expectations for the upcoming ASCO presentation of the KOMET-001 results? And how should we be thinking about what will be in the abstract versus the full presentation? Thank you.

Yes, thanks, Jonathan. Thanks for that. So, as for any changes underway at FDA, as we said in the prepared remarks, we’re not seeing any impact at all. The agency has been responsive, collaborative, productive. So we’re not seeing any effects at all. We requested priority review. We’ll be able to give guidance. We would expect to receive notification from FDA on whether the application has been accepted for review and the PDUFA date here in the second quarter and we can communicate that at that time. But at this point, it’s business as usual. I’ll just add, Jonathan, recall that we have breakthrough therapy designation and NPM1-mutant AML. And as we said at the time, this is when that designation matters because agents that have breakthrough therapy designation generally get a higher priority and more resources within FDA because of course, they are directed at significant unmet needs and there is – and needs for which there’s no available therapy. And so whether or not that’s playing into the fact that we’re not seeing any impact at all, I can’t say, but I think we feel today pretty good about where we are with FDA. With respect to the second part of your question about the monotherapy data, we – again, we’ve answered this question, I think many times. The CR, CRh rate will be between 20% and 30%. We’ll also look at time on treatment, safety and tolerability, all the key considerations. You’ll see much of that articulated in the abstract. The ASCO presentation will have a more fulsome data set, of course, because you can go much beyond the abstract. The timing of those two, they’ll be as of the same data cutoff. But of course, the oral presentation will have more data, of course, relative to the abstract.

Got it. Thanks for taking my questions.

Sure, happy to.

We’ll go next to Salim Syed with Mizuho.

Great. Thanks for the question and the commentary today, Troy and team. I guess, one just for your upcoming expected launch in the NPM1 setting. A lot of people I think are thinking here that at least in terms of CRh rates here, that these two menin inhibitor molecules seem more or less the same. Just curious what your updated market share work is sort of telling you, Troy, how these are going to get used once if and when they’re both on the mark in the relapsed/refractory setting.

Yes, let me – Salim, it’s a good question. Let me comment and then I’d actually ask Brian to maybe add his thoughts. Obviously, let’s have that conversation. I think I understand why you’re asking the question. We keep emphasizing safety, tolerability, clinical activity, it is the whole package. It’s important as a monotherapy. It becomes increasingly important as one goes into combination. We have of course done internal demand studies. I don’t think we’ve ever made that public. But we do believe that ziftomenib will be very competitive in the relapsed/refractory setting. And we’re obviously seeing very strong enrollment in the combo settings, which I think again speaks to its ability to treat more patients and ideally get them to better outcomes overall. But Brian, anything you’d add?

I think you answered that. Thank you, Troy. I think you answered that pretty well. I would just maybe add, as you said, we’ve been doing our demand studies, try to get a better understanding of where we see the potential profile differences between agents that come forward. And I think that what we’re seeing is that this will be a competitive space as we expected, but that we have a very good confidence, I think in the strength of our profile that we will be able to be competitive in that monotherapy launch and we’re going to put the resources behind to support that as well.

Yes. And Salim, to that point, this is one of the advantages of our partnership. We know we’re going to be competing for patients, right? This is – it’s an area of high unmet need. It will be – we think be a competitive dynamic. But we’re planning and we haven’t – will provide greater color on this as we get later in the year. But Brian and his team are working very thoughtfully with our colleagues at Kyowa Kirin and we expect to bring the resources and the focus to bear on competing for every single patient. So – and we’re doing that ideally in the relapsed/refractory setting. But also ultimately we do – we are optimistic that you’re going to see use of these menin inhibitors in earlier lines of therapy and in combination. So there’s a lot of education to be done.

Okay, perfect. Thanks so much.

Of course.

We’ll move next to Jason

Hey team, this is Cameron on for Jason. Congrats on the updates and thanks so much for taking our question. So connecting the dots from some of your earlier comments as you look to additional combination data from KOMET-007 at EHA, starting with the fit population, what in your view would constitute a win from the 7+3 combo, specifically on response rates in KMT2A and NPM1? How does that change now that we should see data in non-adverse risk patients? And then as we start to get additional insights into MRD negativity what would drive confidence here and a potential pathway to accelerate approval for zifto ultimately.

Yes. That’s really good questions, Cameron. Let me ask Mollie if she can speak to those.

Sure. As we’ve shown our frontline fit data in the past, we’re obviously seeing really high rates of response even in the adverse risk patient, and it would be hard to improve upon the 100% response rates we were seeing, nor did we expect to maintain that perfection. But throughout the literature what we’ve seen is that in these patient populations, you expect to see anywhere from a 60% to a 90% CRc rate. So maintaining and not interfering with the efficacy of the backbone and hopefully augmenting it of course, is the goal. How do you augment an ORR rate that’s that impressive? Well, you don’t exactly target the ORR rate as you referenced, we’re looking at other signs as well. Usually most of these patients will become relapsed/refractory within a year. You’re going to see data on patients that are approaching a year’s worth of therapy, so that you can get an idea of maybe the durability of these patients’ responses to this combination of therapy. And obviously we will be showing MRD data as well. However, I’m not sure if we will be able to show a centralized version at the time of the presentation. So it will still be a mix of both bone marrow and peripheral blood, which will make interpretation slightly more difficult. But of course, in bone marrow you expect maybe 40% of patients to achieve MRD negativity. So that should be an anchoring point for looking at the data.

Great. Thank you.

Thanks, Cameron.

We’ll go next to Charles

Hey everyone, thanks for taking the question. I’ll start off by saying congratulations on submitting your NDA in NPM1 AML. Interesting timeline relative to your competitors sNDA even though they hit top line months before you did. But anyways onto the question I’ll ask one actually on farnesyl transferase inhibitors regarding KO-2806. How do you envision the longer-term in combination development with VEGF TKIs in RCC? Just given the movement in that space with next-gen VEGF TKIs, HIF2α as well as checkpoint inhibitors. And how do you see KO-2806 fitting into that as it shapes out longer-term? Thank you.

Yes, Charles, thanks for the question. Mollie, do you want to answer Charles question about how we see KO-2806 fitting into the evolving RCC landscape?

Of course. So I mean, as you point out, there are thankfully new therapies coming into this area of high unmet need, but none of them are going to be curative. And so until there’s actually a cure, there’s always going to be the need for additional therapies. We see the combination of KO-2806 with cabo to be highly synergistic with the way physicians are currently comfortable treating. So they will be able to make use of a drug they’re comfortable with that they’ve seen high rates of response with, and hopefully with the addition of KO-2806, they’ll see deeper, longer and higher rates of response for these patients. So we see a very big potential for KO-2806 to really augment the current treatment paradigms.

Got it. Great. Thank you.

Thanks, Charles.

We’ll go next to Ellen Horste with TD Cowen.

Great. Thank you for taking the question and congrats on the NDA, super exciting. Couple questions. What is Kyowa Kirin strategy to capture the share of the NPM1 market and overcome zifto second to market position? And what points of differentiation do you think will resonate most with investors?

Yes. It’s – so maybe I can take issue just with the thesis of the question. It’s not obvious to us at the moment that we’ll be second to market. We’ve disclosed that we submitted our NDA in March – admittedly end of March, let’s call it, end of Q1. We’ve requested priority review and we have breakthrough therapy designation. Just as you are, we’re waiting to see kind of where the – where our competitors are in terms of their submission timelines and regulatory review. I think under any scenario, it’s going to be very, very close. That’s just our operating hypothesis. If you go back not that long ago, I was hearing from people that we were a year behind or two years behind, kudos to our development and regulatory teams for closing that gap. Unfortunately, there isn’t a large prevalent population of relapsed refractory NPM1 mutant patients. We wish there were, but that actually speaks to the significant unmet medical need. These patients progress and unfortunately passed away within days or weeks if you don’t get them on therapy. So I think where you’re going to end up is a competitive dynamic where physicians have choices and choice is always good for patients. And as Brian said in his prepared remarks to the earlier question, we’re going to mount a significant – we lead commercial strategy and we and Kyowa Kirin are working together. We’re going to be fighting for every patient and we’re going to be looking both to promote within the relapsed/refractory setting and then to educate about the potential for menin inhibitors in earlier lines of therapy and in combination. That’s why you see a comprehensive approach to us moving ziftomenib to what we believe will be first-in-class and best-in-class throughout the treatment continuum. This is the first step. It’s an important step and we’re feeling pretty good about it.

Thank you, Troy. That’s helpful.

Yes, pleasure.

[Operator Instructions] We will move next to Peter Lawson with Barclays.

Thanks for taking my questions. Troy, just on the GIST side of things, what patient segments do you think are going to be more responsive to the combination and the particular subgroups you are going to be focused on, whether it’s the imatinib refractory or naïve.

So, Peter, that’s actually one of the beauties of this program, but I’ll let Mollie fill in the details. That’s a great question and it actually I think you put your finger on sort of what is potentially so transformational about this MOA. Mollie?

Yes. That’s exactly what I was thinking, Troy, is that’s what makes this approach so revolutionary and potentially transformative is that it will be mutationally agnostic. So we do not have to worry about picking the appropriate combination partner for each line of therapy. Using it with imatinib, whether the patient is currently on imatinib or has already failed imatinib and had additional previous lines of therapy, the combination should still work. We affect with ziftomenib as the we affects the KIT transcription and the imatinib affects the KIT stability. So overall, these highly KIT dependent cells are then deprived of what they need to continue being oncogenic from two different mechanisms. And as I said, that should be independent of what the KIT mutation is. So we would, of course, start to show ourselves that it works in a second line plus setting. But we hope to move into the frontline setting as well, because we really think we could be a superb adjunct to imatinib therapy, which physicians are already so comfortable with and which patients tolerate so well.

How do you think that kind of plays out? Does that play out in ORR or PFS and kind of what are the goals, I think or the go forward decisions around those? I know it’s early, but around ORR or PFS.

Yes. So as we look at our preclinical data, we think it’ll be a combination of both. We think that we’ll see – it’s very rare you see a complete response in a GIST patient. So we’re hoping to see potentially deeper responses, longer lasting responses. And again, if we see a response in a patient where imatinib has failed, has now failed or is starting to fail and we can save that response, that’s also a very clear sign that this potential mechanism truly is synergistic and is what these patients need.

Got you. Thank you so much.

And Peter, I just want to pick up on something that Mollie said and this is in response to your question as well as Charles’ question. What you see as you look across our portfolio is we’re taking these targeted therapies and ideally layering them onto standard of care that is either generic or will be generic by the time we get to market. So chemotherapy and AML, potentially cabozantinib and RCC, imatinib and GIST, that if we can take opportunities where the market is very well understood, it’s physician’s first choice and we can make a claim that we can actually do better for your patients. And you don’t – you have the ability to drive premium pricing as well, because you’re not layering on top of another novel therapy. We see that as a really compelling opportunity across both liquid tumors and solid tumors. So we haven’t talked much about the pipeline. There’s just been so much focus on zifto, but that is the theme that you’re beginning to see come together. And we’ll have much more to talk about this in the second half of the year and on into next year.

Perfect. Thank you so much.

We’ll go next to David Dai with UBS.

Great, thanks for taking my questions. And I also want to add my congratulations to a great quarter. So just focusing on Phase 3 KOMET-017 trial, what are some of the gating steps before you’re able to initiate the trial in second half? And then just more specifically around that. So how are the site activations going and what are some earliest reception from trial investigators on the ziftomenib’s profile that could really accelerate your initiation in that trial?

Yes. David, thanks for the question. Maybe I’ll take the first half and then I’ll ask Mollie to speak to what we’re hearing from sites and investigators. We’ve said we’re in study startup. There’s a lot that has to happen for a global Phase 3, contracting, budgeting as you say site initiation. We haven’t been more granular on our guidance beyond saying it’s second half. The team is doing everything it can to pull those timelines in. But as I like to say, it’s first patient in matters, last patient in arguably matters more. So the – our team, I think, increasingly has shown an ability to execute at a very high level, development, regulatory, clinical operations, hopefully soon to be commercial. So we’ll give you more color around these trials as we get into the second half of the year. In terms of what we’re hearing about ziftomenib in the context of O17, let me ask Mollie if she can speak to some of what she and her team are hearing from investigators.

Sure. I mean, really, we have such a good preview of 017 from our 007 trial that it gives us a real good insight into how both the treaters and the patients are feeling. And one of the things we hear most often is that they don’t realize they’re taking another medication. They feel the same or better than they did on the backbone therapies. So we don’t really see that there’s going to be much opposition to including, the addition of ziftomenib within these backbone therapies as well. There’s a lot of excitement. We get contacted directly from people that want to participate. And I think as we share more data from the 007 trial, the excitement will only build. So it’s all been very positive so far.

Thank you so much.

Thanks, David.

We’ll move next to Jeet Mukherjee with BTIG.

Great, thank you for taking the question and congrats again on the NDA submission. So my first question was we do hear anecdotal off label use of other currently approved menin inhibitors in relapsed/refractory NPM1 patients. So my question was what do you think is perhaps needed to pull clinicians who are perhaps familiar and comfortable with one agent over to zifto following a potential approval? Thanks.

Yes. Jeet, thanks for the question. Let me ask Brian if he can speak to it.

Thanks, Jeet. So I’ve heard and we’ve seen reports around some of the competitor agents having some off label usage of NPM1. I think to what Troy’s point earlier is, is that there may we anticipate there may be some experimentation and use of other therapies in this setting, which I think demonstrates the very high unmet in this space. To the point that Troy made earlier, we don’t anticipate that there is a large pool of patients that are just waiting for a therapy to be available. So if there are patients that are currently being prescribed another menin inhibitor, we think that there will still be patients as we get – as we move forward to approval that will still be available for us. And I think our objectives and goals will be able to appropriately communicate the risk benefit profile of our therapy relative to other competitors, so that we can understand and give physicians the information they need, that – what we understand and we think may be a favorable profile relative to others. So I think on the one hand, I’m glad that physicians are excited about the introduction of Menin Inhibition and the treatments, and on the other, I think that gives us a good position for us as we prepare for a launch to kind of be ready to go out there and get every patient possible to put on the ziftomenib.

Great, thanks. Maybe just a quick follow-up with all that’s going on in the FTI franchise between RCC, RAS mutations, and head and neck as well. Just are you looking to advance all these indications in parallel? Or what will it take to make you have a go/no-go decision with all these indications? Thanks.

Yes. That’s actually a very, very good question and very forward looking. Thank you. Just so this goes back to a comment that I made earlier after Peter’s question. I think it’s important that biopharma companies of our size have a compelling sort of standalone proposition that one can finance and execute on independently. And then if you can add on to that and drive increasing uptake in revenue, that’s great. What does that mean? We think we’ll be in a position if the data supports moving forward into RCC and admittedly it’s early days. We haven’t shown you any clinical data. You’ve seen, I think pretty compelling preclinical data, clinical data coming in the second half of the year. If there’s an opportunity, we could arguably do that alone because by the time we reach the market, the partner compound in this case cabozantinib would be likely generic. That’s not true for well, may be true for example, PI3 kinase alpha inhibitors or KRAS inhibitors. There you’re more likely going to need to partner with either a large company or a small company to find the path forward. And I would put that in the bucket of [indiscernible] nice to have. I don’t think you want to have your company’s strategy necessarily dependent on a partner. I think you want to have that as optional and a really high commitment from both parties. But what you’re seeing again, we’re in a great place with Kyowa Kirin in AML. I think we’ll look forward in the future to sharing data in GIST with you. We’ll talk about FTIs. We are trying to identify those products, product opportunities, i.e., the combinations, which Kura can take forward on its own or in the case of zifto with Kyowa Kirin. That’s how – that’s at a high level [indiscernible] how we will think about prioritizing it. Below that then you ask, what are the best agents? Who are the partners? How do we think about working together? But it will be very much a starting with what is best for Kura, for our patients and for our shareholders. We go to the next.

We will go next to George Farmer with Scotiabank.

Hi, thanks for taking my questions. So, Troy, given that you do have BTD with zifto and NPM1 disease, shouldn’t you have a good feel about whether you can get priority review by now? Also, do you think you’ll need that FDA will want to convene an ODAC meeting. And also regarding the co-primary endpoint in your Phase 3’s MRD negativity and CR/CH. Do you need to hit both of those in order for a win or can you just hit one or the other? Thanks.

Yes, George, I’ll take the first two questions and I’ll let Mollie take the endpoint questions. We can’t – look, we’ve said we’re feeling good. There have been no disruptions. The agency has been responsive. I think at this point we’ve said as much as we can say. Next stop is hopefully the dossier is accepted for review and we’re assigned to PDUFA date. We’ll communicate that when it happens. Your second question was, forgive me.

ODAC question.

Oh the ODAC. I think it would be unusual. I don’t think we’re expecting an ODAC here, given this is a palliative setting, given that the agencies expressed a willingness for to grant full approval for agents in relapsed refractory AML. And given George quite frankly that the safety and tolerability profile to Mollie’s point really I think is very strong in the case of ziftomenib. You would never say never, but I don’t think we’re anticipating an ODAC. Mollie, do you want to – I don’t know if you want to add anything Mollie to my first two answers, but could you speak to George’s questions about the endpoints on the Phase 3s?

Sure. No, I mean, I think your first two answers are spot on. We’ll find out about priority review when they formally accept the dossier. As for the co primaries, what I want to correct is they’re not actually co-primary endpoints, they’re dual primary endpoints. So, even if you, for some reason did not win on your accelerated endpoint, so your CR or your MRD negative CR, you could still win in the overall trial with the survival based endpoint. So, that being the EFS or the OS. So you can hit both or just the overall survival endpoint and still have a win.

Okay, thank you.

Yes, thanks George.

We’ll go next to Roger Song with Jefferies.

Great, thanks for the update and then taking our questions. So, the first is a clarification. Maybe, Troy, I’m not sure I misheard that. You say the ASCO abstract and the presentation will be the same data cut. So, just can you just confirm that? And then also, you’re ready to your 017, the first line combination pivotal. How should we think about enrollment given you will soon have approved the drug and you already have approved the drug and then soon, as ziftomenib will be approved in the RNR setting, how should we think about the pivotal first line enrollment timeline?

Yes, Roger, thank you for the questions. So, yes, the abstract and presentation will have the same data cut. And as I said, the full presentation is a more expansive tour through the data. As far as your second question Roger around the dynamic between a potentially approved ziftomenib product and the frontline trial, there really shouldn’t be – well, let me put it this way. There shouldn’t be a drag on enrollment in the frontline trials because obviously that’s a patient population for which no menin inhibitor is approved. And as Mollie indicated in her answers to a couple of questions, we continue to see very robust enrollment in both the intensive and non-intensive setting. I think maybe the reciprocal question of will there be an impact of the frontline studies on the relapsed refractory setting, that I don’t think we know the answer to that. We’ll be watching for that, but I think it’s too early to say at this point whether they’ll have any impact of frontline development on the availability of patients in the commercial setting in the relapsed/refractory excuse me, in the relapsed/refractory setting.

Yes, that’s fair. Thank you.

Thank you.

It appears that we have no further questions at this time. I will now turn the program back over to Troy Wilson for any additional or closing remarks.

Thank you, Jess, and thank you all once again for joining our call today. We’ll be participating at several medical and investor conferences over the next couple of months including ASCO and EHA and look forward to seeing many of you there. We also plan to host a virtual investor event following our oral presentation at ASCO. So look for more details in the coming weeks. In the meantime, if you have any additional questions, please feel free to reach out. Thank you and have a good afternoon and a good evening, everyone.